Sentynl completes asset transfer of CUTX-101 Copper Histidinate product candidate for treatment of… EP News Bureau Dec 6, 2023 A rolling submission of the CUTX-101 New Drug Application (NDA) to the FDA is ongoing, with expected completion in 2024
